<DOC>
	<DOCNO>NCT01355458</DOCNO>
	<brief_summary>Phase 3 efficacy safety study CD07805/47 topical gel subject facial erythema associate rosacea . The study hypothesis CD07805/47 gel , apply topically daily efficacious vehicle provide acceptable safety profile treatment facial erythema associate rosacea .</brief_summary>
	<brief_title>Phase 3 Efficacy Safety Study CD07805/47 Topical Gel Subjects With Facial Erythema Associated With Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Erythema</mesh_term>
	<criteria>Key 1 . Male female least 18 year age old . 2 . A clinical diagnosis facial rosacea . 3 . A Clinician Erythema Assessment ( CEA ) score great equal 3 Screening Baseline/Day 1 ( prior study drug application ) . 4 . A Patient Self Assessment ( PSA ) score great equal 3 Screening Baseline/Day 1 ( prior study drug application ) . Key 1 . Particular form rosacea ( rosacea conglobata , rosacea fulminans , isolated rhinophyma , isolated pustulosis chin ) concomitant facial dermatosis similar rosacea perioral dermatitis , demodicidosis , facial keratosis pilaris , seborrheic dermatitis , acute lupus erythematosus , actinic telangiectasia . 2 . Presence three ( 3 ) facial inflammatory lesion rosacea . 3 . Current treatment monoamine oxidase ( MAO ) inhibitor , barbiturate , opiate , sedative , systemic anesthetic , alpha agonist . 4 . Less 3 month stable dose treatment tricyclic antidepressant , cardiac glycoside , beta blocker antihypertensive agent . 5 . Current diagnosis Raynaud 's syndrome , thromboangiitis obliterans , orthostatic hypotension , severe cardiovascular disease , cerebral coronary insufficiency , renal hepatic impairment , scleroderma , Sj√∂gren 's syndrome , depression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>rosacea</keyword>
</DOC>